Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?

Cynthia B.E. Chee, Kyi-Win KhinMar, Li-H. Sng, Roland Jureen, Jeffery Cutter, Vernon J.M. Lee, Yee-Tang Wang
European Respiratory Journal 2017 50: 1700753; DOI: 10.1183/13993003.00753-2017
Cynthia B.E. Chee
1Respiratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore
2Tuberculosis Control Unit, Tan Tock Seng Hospital, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cynthia_chee@ttsh.com.sg
Kyi-Win KhinMar
2Tuberculosis Control Unit, Tan Tock Seng Hospital, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li-H. Sng
3Dept of Pathology, Singapore General Hospital, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roland Jureen
4National University Health System (NUHS), Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffery Cutter
5Communicable Diseases Division, Ministry of Health, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vernon J.M. Lee
5Communicable Diseases Division, Ministry of Health, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yee-Tang Wang
1Respiratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore
2Tuberculosis Control Unit, Tan Tock Seng Hospital, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

About 30% of MDR pulmonary-TB patients in a SE Asian (Singaporean) sample are eligible for the WHO shorter regimen http://ow.ly/KF3330dMSVs

To the Editor:

Multidrug-resistant tuberculosis (MDR-TB) is a major public health challenge, with an estimated 480 000 new cases emerging globally each year [1]. Treatment success rates using the 20-month conventional World Health Organization (WHO) regimen have been low, being about 52% in 2013 [1]. Observational studies in Bangladesh and several African countries have shown success rates of 84% using a shorter regimen [2–4]. Based on these studies, in May 2016 the WHO conditionally recommended a standardised, shorter 9–12-month regimen for MDR pulmonary tuberculosis (PTB), comprising a 4–6-month intensive phase with a combination of kanamycin, moxifloxacin, prothionamide, clofazimine, pyrazinamide, high-dose isoniazid and ethambutol, followed by a 5-month continuation phase containing moxifloxacin, clofazimine, ethambutol and pyrazinamide [5]. Confirmed resistance (except to isoniazid) or suspected ineffectiveness to a drug in this regimen is one of the exclusion criteria [5].

Several researchers have highlighted the ambiguity of the eligibility criteria and expressed doubts as to the widespread applicability of this regimen [6]. Publications from Europe have reported eligibility rates ranging from 6.2% to 14% [7–10]. Data from Pakistan and Brazil showed more optimistic eligibility rates of 50% or higher [11, 12]. A multicountry population-based survey showed that, although pyrazinamide resistance was significantly associated with rifampicin resistance, this drug might still be effective in 19–63% of patients with rifampicin-resistant TB, and that the worrisome high level of ofloxacin resistance in Pakistan (probably reflecting extensive, unregulated use of fluoroquinolones in some parts of Asia) was tempered by the negligible levels of resistance to fourth-generation fluoroquinolones documented in all survey sites [13]. To our knowledge, there are to date no publications on the eligibility of this regimen among patients with MDR-PTB from South-east Asia, India and China.

Singapore, a country with an intermediate TB incidence in South-east Asia, receives migrant workers and medical tourists from countries with high TB incidence in the region. Since 2008, foreign-born TB cases have accounted for slightly above 40% of the country's TB burden. MDR-TB has been reported in 3% of foreign-born cases of PTB and 0.3% of PTB cases born in Singapore or Malaysia [14].

The diagnosis of MDR/rifampicin-resistant PTB in developing countries is often based solely on the Xpert MTB/Rif assay (Cepheid, Sunnyvale, USA), and many of these countries lack quality-assured laboratory capacity to perform full phenotypic drug susceptibility testing (DST). Information collected by the WHO on DST reporting for fluoroquinolones and second-line injectables indicate that, among MDR/rifampicin-resistant patients with TB notified to the authorities in 2015, only 36% were reported to have DST to these drug classes, with the lowest coverage being in the WHO Western Pacific and South-east Asia regions [1]. In developing countries where the highest burden of MDR-TB exists, the availability of DST for the other drugs in the WHO shorter regimen (i.e., pyrazinamide, ethionamide/prothionamide and clofazimine) is not known. Although the WHO-endorsed Genotype MTBDRsl versions 1 and 2 (Hain LifeScience, Nehren, Germany) detect genotypic resistance to the fluoroquinolones and second-line injectables, there are currently no commercial assays to detect genotypic resistance to pyrazinamide, ethionamide or clofazimine.

Singapore is served by two mycobacterial culture laboratories, the Central TB Laboratory at the Singapore General Hospital and the Microbiology Laboratory of the National University Hospital. Both laboratories routinely perform first-line DST to isoniazid, rifampicin, ethambutol and streptomycin for all patients with positive Mycobacterium tuberculosis complex (MTC) isolates. DST to kanamycin, ofloxacin and ethionamide is routinely performed on isolates resistant to rifampicin and/or isoniazid. DST to pyrazinamide, para-amino salicylic (PAS), clofazimine and capreomycin are performed on request. The critical concentrations used for each of the drugs are as follows: rifampicin 1.0 μg·mL−1, isoniazid 0.1 μg·mL−1, ethambutol 5.0 μg·mL−1, kanamycin 2.5 μg·mL−1, ofloxacin 2.0 μg·mL−1, ethionamide 5.0 μg·mL−1 and clofazimine 0.5 μg·mL−1. All positive MTC culture and DST results are captured in the National TB Registry via electronic linkage to both mycobacterial laboratories because TB is a notifiable disease in Singapore. Patient demographic data, country of origin and type of case (new/previously treated) are captured in the National TB Registry.

Using data from the registry, we analysed the phenotypic DST results to the constituent drugs (except isoniazid) of the shorter WHO regimen of all MDR-PTB cases diagnosed in Singapore from 2002 to 2016 to determine their eligibility for this regimen. Ethics approval was not required, as this was registry data analysed in aggregate form.

During the study period, there were 270 patients with MDR-PTB (202 new and 68 previously treated cases), of whom 49 were born in Singapore, five were born in Malaysia and 216 (80%) were born outside of Singapore/Malaysia. The latter group comprised patients from Indonesia (n=76), Myanmar (n=56), China (n=37), Philippines (n=18), Vietnam (n=15), India (n=7) and Bangladesh (n=4), with one patient each from Saudi Arabia, Tonga and Russia. Nine patients (3.3%) were extensively drug-resistant (XDR) and 29 (10.7%) were pre-XDR cases.

The patients from Saudi Arabia, Tonga and Russia (none of whom had XDR) were excluded from our analysis. For the remaining 267 patients, phenotypic DST results to ethambutol were available for all; to kanamycin and ethionamide in 266 (99.6%), to ofloxacin in 261 (97.8%), to pyrazinamide in 165 (61.8%) and to clofazimine in 105 (39.3%) (table 1). Of those tested, 4.1% (11/266) were resistant to kanamycin, 28.2% (75/266) to ethionamide, 13.4% (35/261) to ofloxacin, 43.4% (116/267) to ethambutol, 43.6% (72/165) to pyrazinamide and 3.8% (4/105) to clofazimine. Of the 267 cases, 190 (71.2%) (137/200 (68.5%) of the new cases and 53/67 (79.1%) of the previously treated cases) were resistant to at least one of the six constituent drugs of the WHO shorter regimen. Excluding ethambutol (in view of the lower reliability of DST for this drug [15]), 142 (53.2%) were resistant to at least one of the other five drugs. Only 22 (8.2%) showed confirmed susceptibility to all six drugs.

View this table:
  • View inline
  • View popup
TABLE 1

Number and percentage of cases resistant to each of the six individual drugs in the shorter World Health Organization regimen, resistant to at least one of the six drugs and resistant to at least one of the five drugs excluding ethambutol, classified according to country of origin

Among MDR-PTB patients from Indonesia and Myanmar, who together accounted for 60% of Singapore's foreign-born cases of MDR-TB, 75% and 71.4%, respectively, were resistant to at least one of the six drugs in the WHO shorter regimen. Patients with MDR-PTB from the Philippines and Singapore/Malaysia had considerably lower rates of resistance to ethambutol (11.1% and 27.8% respectively) and pyrazinamide (30% and 6.8% respectively), but higher rates of ethionamide resistance (44.4% and 48.1% respectively) compared with the patients from the other countries.

Ofloxacin resistance was significantly more likely among those previously treated (11.2% versus 25%, p=0.007). There was no significant difference in the rates of resistance to kanamycin (3.0% versus 7.6%, p=0.10), ethionamide (28.5% versus 27.3%, p=0.85), ethambutol (42.0% versus 47.8%, p=0.41), pyrazinamide (41.6% versus 50.0%, p=0.35), and clofazimine (2.4% versus 10.0%, p=0.11) between new and previously treated cases.

Our study has several limitations. Only 62% and 39% of cases had DST performed to pyrazinamide and clofazimine, respectively. The small number of cases in our cohort may not be representative of patients with MDR-TB in the respective countries of origin. Information pertaining to new or previously treated TB and country of origin was subject to the accuracy of the notifying physician's submission to the registry.

Our study shows that only about 30% of patients with MDR-PTB diagnosed in this sample from South-east Asia would be eligible for the WHO shorter MDR-TB treatment regimen. Ignoring ethambutol resistance, approximately 50% of these cases would be eligible. However, in the absence of individual full DST results, we advise caution in the use of this regimen in patients from the South-east Asian countries represented in our study.

Footnotes

  • Conflict of interest: None declared.

  • Received April 11, 2017.
  • Accepted May 6, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    Global tuberculosis report 2016. Geneva, World Health Organization, 2016. http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1
  2. ↵
    1. Van Deun A,
    2. Maug AKJ,
    3. Salim MAH
    , et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684–692.
    OpenUrlCrossRefPubMedWeb of Science
    1. Kuaban C,
    2. Noeske J,
    3. Rieder HL
    , et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517–524.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Piubello A,
    2. Harouna SH,
    3. Souleymane MB
    , et al. High cure rate with standardized short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188–1194.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Falzon D,
    2. Schunemann H,
    3. Harausz E
    , et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Varaine F,
    2. Guglielmetti L,
    3. Huerga H
    , et al. Eligibility for the shorter multidrug resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations. Am J Respir Crit Care Med 2016; 194: 1028–1029.
    OpenUrl
  6. ↵
    1. Balabanova Y,
    2. Fiebig L,
    3. Ignatyeva O
    , et al. Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule? Thorax 2017; in press [https://doi.org/10.1136/thoraxjnl-2016-209841].
    1. Lange C,
    2. Duarte R,
    3. Frechet-Jachym M
    , et al. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe. Am J Respir Crit Care Med 2016; 194: 1029–1031.
    OpenUrl
    1. van der Werf MJ,
    2. Hollo V,
    3. Kodmon C
    , et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J 2017; 49: 1601992.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Sotgiu G,
    2. Tiberi S,
    3. D'Ambrosio L
    , et al. Faster for less: the new shorter regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503–1507.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Jarvaid A,
    2. Ahmad N,
    3. Khan AH
    , et al. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Eur Respir J 2017; 49: 1601967.
    OpenUrl
  9. ↵
    1. Dalcolmo M,
    2. Gayoso R,
    3. Sotgiu G
    , et al. Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015. Eur Respir J 2017; 49: 1602309.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Zignol M,
    2. Dean AS,
    3. Alikhanova N
    , et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 2016; 16: 1185–1192.
    OpenUrlCrossRef
  11. ↵
    Communicable diseases surveillance in Singapore 2015. Singapore, Singapore Ministry of Health, 2016. www.moh.gov.sg/content/dam/moh_web/Publications/Reports/2016/Full%20Version.pdf
  12. ↵
    1. Yakrus MA,
    2. Driscol J,
    3. McAlister A
    , et al. Molecular and growth-based drug susceptibility testing of Mycobacterium tuberculosis complex for ethambutol resistance in the United States. Tuberc Res Treat 2016; 2016: 3404860.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 2 Table of Contents
European Respiratory Journal: 50 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
Cynthia B.E. Chee, Kyi-Win KhinMar, Li-H. Sng, Roland Jureen, Jeffery Cutter, Vernon J.M. Lee, Yee-Tang Wang
European Respiratory Journal Aug 2017, 50 (2) 1700753; DOI: 10.1183/13993003.00753-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
Cynthia B.E. Chee, Kyi-Win KhinMar, Li-H. Sng, Roland Jureen, Jeffery Cutter, Vernon J.M. Lee, Yee-Tang Wang
European Respiratory Journal Aug 2017, 50 (2) 1700753; DOI: 10.1183/13993003.00753-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Rifapentine access in Europe: concerns over key TB treatment
  • P. aeruginosa membrane vesicles cause endothelial barrier failure
  • Mortality after admission with pneumonia higher than after admission with COPD exacerbation
Show more Agora

Research letters

  • Rifapentine access in Europe: concerns over key TB treatment
  • P. aeruginosa membrane vesicles cause endothelial barrier failure
  • Mortality after admission with pneumonia higher than after admission with COPD exacerbation
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society